key: cord-0776174-utolqhmd
authors: Penney, Jessica; Jung, Amanda; Koethe, Benjamin; Doron, Shira
title: Cycle threshold values and SARS‐CoV‐2: Relationship to demographic characteristics and disease severity
date: 2022-04-08
journal: J Med Virol
DOI: 10.1002/jmv.27752
sha: dada0bcefdd55874fb96787539a75d22816e6d61
doc_id: 776174
cord_uid: utolqhmd

Cycle threshold (Ct), or the number of cycles required to amplify viral RNA to a detectable level, provides an estimate of viral load. Previous studies have demonstrated mixed results in regard to the association between SARS‐CoV‐2 Ct from real‐time reverse transcriptase PCR (rRT‐PCR) testing to patient outcomes, and there is less data on the relationship between Ct and patient characteristics. This was a retrospective study of 256 patients tested at a tertiary care emergency department from March to July 2020 via nasopharyngeal rRT‐PCR testing utilizing the Abbott M2000 SARS‐CoV‐2 assay. Kruskal–Wallis, univariable, and multivariable logistic regression were used where appropriate for analysis. There were no significant differences in Ct value by demographic characteristics including age, sex, race, or ethnicity. Ct increased with time since symptom onset (p < 0.001), and increasing Ct was associated with increased odds of severe disease (odds ratio: 1.05, 95% confidence interval: 1.0–1.11). Ct was not found to be associated with patient demographic characteristics and increasing Ct was found to be associated with increased odds of severe disease. Continued study will allow us to better comprehend the complex factors that contribute to the risk for severe outcomes due to SARS‐CoV‐2 infection.

Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has been responsible for more than 180 million cases and almost 4 million deaths worldwide. 1 Despite substantial advances in our knowledge of this disease, research continues to fully understand SARS-CoV-2, a clade within the family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus, species Severe acute respiratory syndrome-related virus, 2 particularly in understanding factors related to patient prognosis after infection. Early studies have found that certain individuals are at greater risk for poor outcomes after developing COVID-19, including older individuals, those who are obese, and patients with multiple comorbid conditions. [3] [4] [5] The primary method of diagnosis of SARS-CoV-2 is currently by real-time reverse transcriptase PCR (rRT-PCR). These rRT-PCR tests amplify and detect viral genetic sequences, and a fluorescence signal increases proportionally to the amount of amplified nucleic acid, enabling the quantification of RNA in the sample. 6 This signal is expressed as the cycle threshold (Ct), or the number of cycles required to amplify viral RNA to a detectable level, which provides a quantifiable estimate of viral load. 6 The Ct value is inversely related to viral load 6 and has been used as a proxy for viral in a number of studies 7-10 given the more resource intensive effort required of direct viral load measurement.

Previous studies have found mixed results with regard to the association between Ct and patient outcomes, including risk for intubation, admission to an intensive care unit, and in-hospital survival. 7, 8, 11 The purpose of this observational study was to evaluate the relationship between Ct and patient sociodemographic and clinical characteristics, as well as the relationship between Ct and disease severity, to better understand the role of Ct in estimating patients' risk for adverse outcomes. 

Testing was performed using the Abbott M2000 SARS-CoV-2 assay. This assay is an rRT-PCR dual-target assay for the RNA polymerase (RdRp) and N genes of the SARS-CoV-2 virus 12 and has a positive cutoff value of 31.5. This assay has been demonstrated to have high sensitivity (93%) and specificity (100%) for SARS-CoV-2 13 and allows for the determination of Ct values. This assay utilizes negative and positive controls to evaluate the validity of testing, 12 and all providers performing the testing were trained in appropriate NP swab collection. 

Differences in Ct values by sex, age, race, and ethnicity were compared by Kruskal-Wallis testing. Univariable and multivariable logistic regression analyses were used to evaluate the relationship between time since symptom onset and Ct, and to analyze Ct as a predictor for severe disease at the time of testing or at the point of greatest severity in the patient's disease course. Multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in a standard manner. Model fit was assessed using the C statistic. For all analyses, p values of <0.05 were considered statistically significant. All statistical analysis was performed using SAS 9.4 statistical software.

A total of 256 patients satisfied our study criteria. The mean age of the study population was 55.5 years, 45% were women, 40% were White, 22% were Black, 16% were Asian and 17% were Hispanic.

Medical comorbidities were present in 69.5% of the population, with 23% having more than two medical comorbidities. In terms of disease severity, 8.6% were asymptomatic, 21.9% experienced mild disease, 33.6% had moderate disease, 12.9% had severe disease, and 23% experienced critical disease. Median time since symptom onset was 6 days.

There were no significant differences in Ct values according to patient's age, sex, race, or ethnicity ( On the other hand, a prospective study investigating transmission among household members with a SARS-CoV-2 exposure failed to find an association between Ct and age, race, or ethnicity, consistent with our findings. 9 However, the relationship of Ct values with race and ethnicity is an area that warrants continued study given observed disparities in disease outcomes due to SARS-CoV-2 infection. 15, 16 In the present study, greater disease severity was associated with 18 Consistent with this, patients for whom hospitalization was required were found to have presented later in the disease course in the New York study. 11 Another study conducted at a large academic center also found no association

between Ct values and disease severity or mortality, which was consistent with our findings. 10 In our study while we did find, like Our study provides insights into the patient characteristics and outcomes associated with SARS-CoV-2 infection during a time of rapidly changing viral transmission. Our study has several limitations, however, that need to be kept in mind when interpreting the results.

It was conducted over a relatively short period of time at a single institution and included a relatively small number of patients.

However, our patient population is unique in that the study institution serves a larger Asian American population than those in other studies, providing new information on this race/ethnicity.

Another limitation is that to maintain consistency in testing results, we only analyzed Ct values from one diagnostic testing platform; therefore, findings may not be applicable to all SARS-CoV-2 assays.

However, this testing platform has been well-validated 19 ; thus, we suspect that our findings may also be applicable to other diagnostic assays.

In conclusion, we found that SARS-CoV-2 viral loads as 

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

To interpret the SARS-CoV-2 test, consider the cycle threshold value

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019

Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection

Epidemiological correlates of polymerase chain reaction cycle threshold values in the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Lack of correlation between the SARS-CoV-2 cycle threshold (C t ) value and clinical outcomes in patients with COVID-19

Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance

COVID-19) Treatment Guidelines. National Institutes of Health

Assessment of community-level disparities in coronavirus disease 2019 (COVID-19) infections and deaths in large US metropolitan areas

Association of social and economic inequality with coronavirus disease 2019 incidence and mortality across US counties

SARS-CoV-2 viral load predicts COVID-19 mortality

Temporal dynamics in viral shedding and transmissibility of COVID-19

Verification and validation of SARS-CoV-2 assay performance on the Abbott m2000 and Alinity m Systems

Cycle threshold values and SARS-CoV-2: Relationship to demographic characteristics and disease severity